EPT Disclosure

RNS Number:0467E
GoldmanSachs International
05 June 2006

                                                                    FORM 38.5(a)



                 DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS

                      WITH RECOGNISED INTERMEDIARY STATUS

                      DEALING IN A CLIENT-SERVING CAPACITY

                      (Rule 38.5(a) of the Takeover Code)





1.         KEY INFORMATION


Name of exempt principal trader                Goldman Sachs International

Company dealt in                               CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC

Class of relevant security to which the        Ordinary Shares
dealings being disclosed relate (Note 1)

Date of dealing                                02 June 2006






2.         DEALINGS (Note 2)



(a)        Purchases and sales


Total number of securities purchased   Highest price paid (Note 3)           Lowest price paid (Note 3)


0




Total number of securities sold        Highest price received (Note 3)       Lowest price received (Note 3)


40945                                  13.155 GBP                            13.0617 GBP



 (b)       Derivatives transactions (other than options)


Product name,         Long/short (Note 4)       Number of securities (Note 5)        Price per unit (Note 3)

e.g. CFD
CFD                   Long                      8401                                 13.0696 GBP
CFD                   Long                      12127                                13.0696 GBP
CFD                   Long                      14252                                13.0696 GBP
CFD                   Long                      2875                                 13.0696 GBP
CFD                   Long                      1850                                 13.1458 GBP
CFD                   Short                     1440                                 13.0617 GBP







(c)        Options transactions in respect of existing securities

(i)         Writing, selling, purchasing or varying


Product name,   Writing, selling, Number of securities to  Exercise       Type, e.g.   Expiry     Option money
                  purchasing,     which the option relates                American,
e.g. call       varying etc.      (Note 5)                 price          European     date       paid/received per
option                                                                    etc.                    unit (Note 3)





(ii)        Exercising


Product name, e.g. call option         Number of securities                  Exercise price per unit (Note 3)





3.         OTHER INFORMATION



Agreements, arrangements or understandings relating to options or derivatives




Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating
to the voting rights of any relevant securities under any option referred to on this form or relating to the voting
rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is
referenced. If none, this should be stated.











Date of disclosure                                                05 June 2006

Contact name                                                      Peter Highton

Telephone number                                                  [phone]

Name of offeree/offeror with which connected                      AstraZeneca
Nature of connection (Note 6)                                     Advisor






Notes



The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website at
www.thetakeoverpanel.org.uk






                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

EMMSSEFFISMSEEM